rss
Br J Ophthalmol 2007;91:449-454 doi:10.1136/bjo.2006.106336
  • Clinical science
    • Extended reports

Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema

  1. Masahiko Shimura1,
  2. Toru Nakazawa2,
  3. Kanako Yasuda1,
  4. Takashi Shiono3,
  5. Kohji Nishida2
  1. 1Department of Ophthalmology, NTT East Japan Tohoku Hospital, Sendai, Miyagi, Japan
  2. 2Department of Ophthalmology, Tohoku University, Graduate School of Medicine, Sendai, Japan
  3. 3Shiono Eye Center, Sendai, Japan
  1. Correspondence to: Dr M Shimura Department of Ophthalmology, NTT East Japan Tohoku Hospital, 2-29-1, Yamato, Wakabayashi, Sendai, Miyagi 984-8560, Japan; masahiko{at}v101.vaio.ne.jp
  • Accepted 12 October 2006
  • Published Online First 31 October 2006

Abstract

Aim: To prospectively evaluate the efficacy of subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G-PC) for the treatment of diffuse diabetic macular oedema (DDME).

Methods: 42 eyes of 37 consecutive patients with DDME were studied. 1 week before G-PC, 21 eyes received TA subtenon injection, and the other eyes served as control. The clinical course of visual acuity (VA) and foveal thickness (FT) was monitored for up to 24 weeks after G-PC. Mean deviation (MD) of perimetry with 30-2 program on Humphrey Perimeter (Zeiss-Humphrey, Dublin, California, USA) was also measured. The average laser intensity was recorded.

Results: After TA injection, FT and VA were improved, and subsequent G-PC maintained the improvement for up to 24 weeks without recurrence of diffuse diabetic macular oedema. In contrast, G-PC without TA injection induced transient worsening of FT and VA, then both were gradually improved. At 24 weeks after G-PC, MD in the TA-injected eyes was better than those in control. The required laser intensity in TA-injected eyes was less than that for control.

Conclusion: Subtenon injection of TA prior to G-PC allows for treatment with a lower intensity of laser spots and also prevents the decrease in central visual field sensitivity, all of which have clinical advantages for G-PC.

Footnotes

  • Published Online First 31 October 2006

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjo.2006.106336v1
    2. 91/4/449 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.